在Piper Sandler的看涨下，Lenz股价上涨22%

Lenz Therapeutics (NASDAQ:LENZ) stock was up 22% in afternoon trading Wednesday in the wake of a bullish note on the company by Piper Sandler.

Piper Sandler initiated coverage of the stock with an overweight rating, citing Lenz’s topical treatment LNZ100/101 for the treatment of presbyopia, or far-sightedness.

The investment bank said it saw presbyopia as a “crystal clear compelling commercial opportunity,” adding it was “conservatively” estimating potential peak US sales for the product at $500M+.

Piper Sandler set its price target at $28.

Lenz went public through a merger with publicly traded Graphite Bio in November 2023.